Avalon GloboCare Corp.
Index- P/E- EPS (ttm)-0.10 Insider Own63.57% Shs Outstand88.50M Perf Week6.14%
Market Cap42.30M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float32.74M Perf Month-17.51%
Income-8.80M PEG- EPS next Q- Inst Own1.00% Short Float1.52% Perf Quarter-33.35%
Sales1.40M P/S30.21 EPS this Y32.90% Inst Trans-17.56% Short Ratio6.98 Perf Half Y-47.52%
Book/sh0.01 P/B46.70 EPS next Y- ROA-86.50% Target Price- Perf Year-52.99%
Cash/sh0.01 P/C84.60 EPS next 5Y- ROE-372.30% 52W Range0.40 - 1.19 Perf YTD-43.05%
Dividend- P/FCF- EPS past 5Y- ROI-140.20% 52W High-60.76% Beta0.91
Dividend %- Quick Ratio0.20 Sales past 5Y17.70% Gross Margin30.10% 52W Low16.58% ATR0.05
Employees5 Current Ratio0.20 Sales Q/Q0.00% Oper. Margin- RSI (14)46.08 Volatility8.48% 9.26%
OptionableNo Debt/Eq2.46 EPS Q/Q17.50% Profit Margin- Rel Volume0.38 Prev Close0.47
ShortableYes LT Debt/Eq2.46 Earnings- Payout- Avg Volume71.45K Price0.47
Recom- SMA20-5.30% SMA50-10.27% SMA200-39.31% Volume27,116 Change-1.68%
Jun-30-22 09:00AM  
Jun-01-22 06:26AM  
May-25-22 09:00AM  
May-18-22 09:00AM  
May-10-22 11:10AM  
Apr-27-22 09:00AM  
Feb-14-22 11:57AM  
Jan-04-22 09:00AM  
Dec-22-21 09:00AM  
Dec-09-21 09:00AM  
Dec-06-21 04:18AM  
Nov-15-21 05:20PM  
Nov-11-21 11:25PM  
Oct-14-21 09:20AM  
Oct-07-21 09:01AM  
Sep-30-21 10:52AM  
Sep-23-21 09:00AM  
Sep-13-21 09:30AM  
Sep-09-21 04:32AM  
Sep-08-21 12:11PM  
Aug-04-21 09:00AM  
Jul-20-21 01:30PM  
Jul-19-21 10:30AM  
Jul-18-21 09:00AM  
Jul-16-21 09:00PM  
Jul-01-21 09:00AM  
Jun-28-21 09:04AM  
Jun-21-21 09:00AM  
Jun-18-21 07:32PM  
Jun-15-21 11:28PM  
Jun-14-21 05:47PM  
Jun-11-21 09:00AM  
Jun-09-21 01:47AM  
Jun-08-21 09:00AM  
Mar-29-21 09:25AM  
Mar-22-21 09:00AM  
Feb-09-21 10:30AM  
Jan-23-21 01:24AM  
Dec-30-20 09:00AM  
Nov-16-20 11:37PM  
Oct-22-20 08:30AM  
Sep-03-20 11:11AM  
Sep-01-20 10:24AM  
Aug-19-20 11:03AM  
Aug-12-20 09:00AM  
Jul-13-20 09:00AM  
Jul-03-20 02:37PM  
Jun-29-20 09:30AM  
Jun-25-20 09:00AM  
Jun-16-20 09:00AM  
Jun-11-20 09:00AM  
Jun-08-20 09:00AM  
May-08-20 09:00AM  
Apr-28-20 09:00AM  
Apr-20-20 08:30AM  
Feb-24-20 08:30AM  
Feb-04-20 09:00AM  
Jan-14-20 06:38AM  
Jan-06-20 08:30AM  
Dec-20-19 08:30AM  
Nov-20-19 08:30AM  
Nov-15-19 05:26AM  
Oct-21-19 08:00AM  
Sep-19-19 08:00AM  
Sep-17-19 03:04PM  
Sep-03-19 08:00AM  
Jul-22-19 09:00PM  
Jul-15-19 08:00AM  
Jun-26-19 08:30AM  
Jun-18-19 08:00AM  
Jun-13-19 08:00AM  
Jun-10-19 08:00AM  
May-21-19 09:00AM  
Apr-25-19 08:58AM  
Apr-24-19 08:00AM  
Apr-17-19 08:00AM  
Apr-08-19 08:35AM  
Mar-06-19 08:00AM  
Feb-26-19 08:00AM  
Feb-11-19 08:30AM  
Feb-04-19 08:15AM  
Jan-29-19 10:29AM  
Jan-28-19 08:45AM  
Jan-23-19 01:44PM  
Jan-16-19 04:00PM  
Jan-15-19 08:00AM  
Jan-03-19 09:00AM  
Dec-26-18 10:43AM  
Dec-19-18 08:00AM  
Nov-13-18 09:05AM  
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.